We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Steris (STE) Q4 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
Analysts on Wall Street project that Steris (STE - Free Report) will announce quarterly earnings of $2.41 per share in its forthcoming report, representing an increase of 4.8% year over year. Revenues are projected to reach $1.46 billion, increasing 5.7% from the same quarter last year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Steris metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts expect 'Revenues- Healthcare' to come in at $947.46 million. The estimate points to a change of +7.1% from the year-ago quarter.
It is projected by analysts that the 'Revenues- Dental' will reach $107.16 million. The estimate suggests a change of +3.5% year over year.
Analysts predict that the 'Revenues- Life Sciences' will reach $161.56 million. The estimate suggests a change of +2.6% year over year.
Based on the collective assessment of analysts, 'Revenues- Applied Sterilization Technologies' should arrive at $248.19 million. The estimate points to a change of +3.8% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenues- Life Sciences- Service' of $44.74 million. The estimate points to a change of +10.2% from the year-ago quarter.
Analysts forecast 'Revenues- Life Sciences- Capital equipment' to reach $50.35 million. The estimate indicates a change of +4.2% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Healthcare Products- Service' reaching $343.53 million. The estimate indicates a year-over-year change of +9.2%.
The consensus among analysts is that 'Revenues- Healthcare Products- Capital equipment' will reach $284.16 million. The estimate indicates a year-over-year change of +2.3%.
According to the collective judgment of analysts, 'Revenues- Healthcare Products- Consumables' should come in at $321.13 million. The estimate suggests a change of +9.8% year over year.
The combined assessment of analysts suggests that 'Revenues- Life Sciences- Consumables' will likely reach $67.53 million. The estimate indicates a change of -1.5% from the prior-year quarter.
The consensus estimate for 'Operating income / (loss)- Healthcare' stands at $219.64 million. Compared to the current estimate, the company reported $208.79 million in the same quarter of the previous year.
The average prediction of analysts places 'Operating income / (loss)- Life Sciences' at $62.38 million. Compared to the present estimate, the company reported $61.05 million in the same quarter last year.
Shares of Steris have experienced a change of -3.4% in the past month compared to the -2.7% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), STE is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exploring Analyst Estimates for Steris (STE) Q4 Earnings, Beyond Revenue and EPS
Analysts on Wall Street project that Steris (STE - Free Report) will announce quarterly earnings of $2.41 per share in its forthcoming report, representing an increase of 4.8% year over year. Revenues are projected to reach $1.46 billion, increasing 5.7% from the same quarter last year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Steris metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts expect 'Revenues- Healthcare' to come in at $947.46 million. The estimate points to a change of +7.1% from the year-ago quarter.
It is projected by analysts that the 'Revenues- Dental' will reach $107.16 million. The estimate suggests a change of +3.5% year over year.
Analysts predict that the 'Revenues- Life Sciences' will reach $161.56 million. The estimate suggests a change of +2.6% year over year.
Based on the collective assessment of analysts, 'Revenues- Applied Sterilization Technologies' should arrive at $248.19 million. The estimate points to a change of +3.8% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenues- Life Sciences- Service' of $44.74 million. The estimate points to a change of +10.2% from the year-ago quarter.
Analysts forecast 'Revenues- Life Sciences- Capital equipment' to reach $50.35 million. The estimate indicates a change of +4.2% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Healthcare Products- Service' reaching $343.53 million. The estimate indicates a year-over-year change of +9.2%.
The consensus among analysts is that 'Revenues- Healthcare Products- Capital equipment' will reach $284.16 million. The estimate indicates a year-over-year change of +2.3%.
According to the collective judgment of analysts, 'Revenues- Healthcare Products- Consumables' should come in at $321.13 million. The estimate suggests a change of +9.8% year over year.
The combined assessment of analysts suggests that 'Revenues- Life Sciences- Consumables' will likely reach $67.53 million. The estimate indicates a change of -1.5% from the prior-year quarter.
The consensus estimate for 'Operating income / (loss)- Healthcare' stands at $219.64 million. Compared to the current estimate, the company reported $208.79 million in the same quarter of the previous year.
The average prediction of analysts places 'Operating income / (loss)- Life Sciences' at $62.38 million. Compared to the present estimate, the company reported $61.05 million in the same quarter last year.
View all Key Company Metrics for Steris here>>>
Shares of Steris have experienced a change of -3.4% in the past month compared to the -2.7% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), STE is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>